Want to see CVRX full AI Analyst Report?
CVRX Stock Chart & Stats
$7.36
-$0.03(-0.21%)
At close: 4:00 PM EST
$7.36
-$0.03(-0.21%)
Day’s Range― - ―
52-Week Range$4.37 - $11.30
Previous CloseN/A
Volume20.10K
Average Volume (3M)197.28K
Market Cap
$139.84M
Enterprise Value$115.26M
Total Cash (Recent Filing)$72.30M
Total Debt (Recent Filing)$59.40M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 04, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding26,535,944
10 Day Avg. Volume162,574
30 Day Avg. Volume197,283
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.71
Price to Sales (P/S)3.27
P/FCF Ratio-4.54
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit2.28
Enterprise Value/Ebitda-2.51
Forecast
1Y Price Target
$10.50Price Target Upside42.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$65.33M
Bulls Say, Bears Say
Bulls Say
High Gross Margins / Product EconomicsSustained gross margins near the mid-80s reflect strong unit economics for Barostim, driven by higher ASPs and manufacturing efficiency. Durable high margins provide a structural cushion as sales scale, enabling the company to retain incremental revenue to fund commercialization and reduce breakeven risk over months.
Commercial Footprint ExpansionConsistent procedure growth and a rising base of trained implanting centers and sales territories indicate durable market penetration. Expanding clinician adoption and account coverage create a self-reinforcing growth runway, increasing referral volumes and reducing per-unit commercial cost as utilization intensifies.
Reimbursement Progress (Category I CPT)Transition to a Category I CPT code materially strengthens reimbursement architecture, reducing payer barriers and making hospital adoption more predictable. Improved Medicare Advantage approval trends signal a structural improvement in access that supports sustained procedure growth and revenue visibility over time.
Bears Say
Persistent Cash Burn And Negative FCFOngoing negative operating and free cash flow indicates the business requires continuous external funding or significant margin/volume improvements to reach self-sufficiency. Over a multi-month horizon this raises dilution and financing risk, constraining investments or forcing slower commercialization if capital tightens.
Rising Leverage And Compressed EquityMaterial increase in leverage and a much smaller equity cushion reduce financial flexibility and increase sensitivity to interest rates and reimbursement shocks. Higher debt levels constrain strategic optionality and heighten refinancing or covenant risks over the medium term as revenue growth must absorb fixed financial costs.
Multi-year Timeline For BENEFIT-HF TAM ExpansionWhile BENEFIT-HF could materially expand addressable market, the trial's multi-year enrollment and follow-up timetable mean TAM-driven revenue gains are distant. Relying on this outcome creates a long horizon risk and sustains elevated R&D and commercial investment needs without near-term payoff.
CVRx News
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $4.37 and its highest was $11.30 in the past 12 months.
What is CVRx’s market cap?
CVRx’s market cap is $139.84M.
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is Aug 04, 2026 which is in 25 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on May 11, 2026. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.504 by $0.004.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -0.53.
How many shares outstanding does CVRx have?
CVRx has 26,535,944 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.504. Following the earnings report the stock price went down -23.844%.
Which hedge fund is a major shareholder of CVRx?
Currently, no hedge funds are holding shares in CVRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CVRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (42.66% Upside)
$10.50 (42.66% Upside)
Blogger Sentiment
Bullish
CVRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 207.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.42%
12-Months-Change
Fundamentals
Return on Equity
-120.77%
Trailing 12-Months
Asset Growth
-23.04%
Trailing 12-Months
Company Description
CVRx
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
CVRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly constructive operational and commercial picture: strong top-line growth (+20% total, +22% U.S.), margin expansion (87% gross margin), ASP improvement and clear progress on the major clinical trial (BENEFIT-HF) and reimbursement milestones (Category I CPT code). Near-term headwinds are primarily administrative and timing-related (Medicare Advantage prior authorization volatility), plus continued operating losses and elevated operating expense guidance. The positives — revenue acceleration, improving gross margin, clinical trial activation, and reimbursement progress — outweigh the short-term challenges, which management characterizes as addressable and temporary.View all CVRX earnings summariesCVRX Stock 12 Month Forecast
Average Price Target
$10.50
▲(42.66% Upside)
Technical Analysis
Ownership Overview
29.03% Insiders
6.20% Mutual Funds
31.86% Other Institutional Investors
26.45% Public Companies and
Individual Investors